BLOODPAC Quarterly Newsletter: Q2 2023
Spring 2023 News
At our invite-only Q2 meeting at ASCO, several working groups presented on their progress to date. Thank you to all attendees for a productive and thoughtful discussion, allowing us to align on next steps and continue meeting our promise to cancer patients and the liquid biopsy community.
We're excited to welcome Jon Baden (Head of Solid Tumor Oncology Diagnostics, BMS) and Angela Silvestro (Director, Companion Diagnostics, GSK) to BLOODPAC's Scientific Co-Chair Committee!
BLOODPAC initiated an open comment period on our generic protocols for the analytical validation of ctDNA assays. Our goal is to learn how the community uses these protocols and whether any updates are warranted. If you've read or used the protocols, we'd love to hear from you by July 24th! You can find the full text of the protocols and the feedback form here.
At AACR, BLOODPAC member Jon Baden (BMS) represented the consortium on a panel discussion with the FDA entitled "Liquid Biopsies for Curative-Intent Solid Tumor Drug Development." We had a great turnout, with over 250 attendees!
Upcoming Events
June 27th, 2023 at 10am ET: BLOODPAC Executive Director Lauren C. Leiman will be hosting a webinar on analytical validation in MRD assays sponsored by Horizon Discovery Ltd, a BLOODPAC member organization. Tune in for a live Q&A after the talk! More info and registration here.
August 21st at 9:30am ET: In this session at the Next Generation Dx 2023 Conference, BLOODPAC Executive Director Lauren C. Leiman will lead a discussion on the organization's work in developing and executing a strategic plan for MRD implementation. Panelists will include BLOODPAC members Gregory Jones (Head of Precision Diagnostics, NeoGenomics) and Christina Lockwood (Associate Professor, University of Washington).
August 21st at 4pm ET: BLOODPAC will be running a second session at the Next Generation Dx 2023 Conference discussing our work in standards and framework development, education, and access coordination for multi-cancer early detection (MCED). See here for more information on this event.
September 6-7, 2023: Mark your calendars for our fall Q3 meeting on September 6th and 7th in Omaha, Nebraska, hosted by Streck!
September 14-15, 2023: Jennifer Dickey (Head of Regulatory and Quality, PDGx) will presenting on BLOODPAC's protocols for analytical validation of ctDNA assays at an in-person NCI workshop entitled ctDNA in Cancer Treatment and Clinical Care. Details will be made available later in the summer.
September 20-23, 2023: BLOODPAC will be at the 6th annual Advances in Circulating Tumor Cells conference! Lauren C. Leiman (Executive Director, BLOODPAC) will present on the Global Regulatory working group's progress in the addressing the need for international regulatory standards in liquid biopsy development and implementation.
